Why:
- The business that earns the money is capped, and the business that carries the story earns nothing yet. Symbiotec dominates a pool of steroid drug ingredients worth only about US$720 million growing 1 to 3% a year, where it already holds around 38% of volume, and its share is falling in the three largest products by value (T1). The growth story is two new plants, built for ₹87 crore, that produced a combined operating loss last year: the injectables plant is still applying for approvals with no signed sales partner, and the fermentation plant's contract revenue actually fell 84% in the year it opened.
- Reported profit growth last year was made on the tax line. A one-time ₹16 crore deferred-tax credit turned what would have been a second straight year of falling profit into 14% growth (T1). Next year the arithmetic points down: a roughly ₹45 crore depreciation step-up from the new plants lands against about ₹6.5 crore of interest saved by the offer's debt repayment.
- The offer is 91% an exit, and the promoter's buying was done with borrowed money. ₹1,607 crore of the ₹1,757 crore deal goes to two private equity funds selling after eight years. The family did put about ₹184 crore into a rights issue, but it borrowed up to ₹197 crore against its own holding company to do it, and 13.2% of the company's shares go back into pledge two business days after listing (T1).
Valuation at the band
| Floor ₹938 (T1) | Cap ₹988 (T1) | |
|---|---|---|
| Bid window | 24 to 27 August 2026 | |
| Fresh shares | 1,599,147 | 1,518,219 |
| Post-issue shares | 64,333,998 | 64,253,070 |
| Market value | ₹6,035 cr | ₹6,348 cr |
| Price to earnings | 54.9x | 57.8x |
| Price to earnings, stripping the tax credit | 64.3x | 67.7x |
| Enterprise value to operating profit | 27.7x | 29.0x |
| Same, after the ₹113 cr of debt the issue repays | 27.2x | 28.5x |
| Promoter group holding after | 33.1% | 33.3% |
The company's own peer table runs from 61x to 109x earnings with an average of 88x (T1), so the band sits below every peer it names, though none of those peers sells into the same market. The price does not change the verdict either way: the six ratings below judge the business and the offer's shape, not what it costs.
The story
What a buyer is really buying is two empty new factories attached to one very good old one. The old business, steroid drug ingredients, is 96% of revenue and earns around 30% on its capital. The new plants (injectable vials and contract fermentation) hold 63% of the company's capital and earned a loss last year. Everything in the next three years depends on whether they fill.
What this business is
Symbiotec, from Indore, makes the active ingredients for steroid medicines: hydrocortisone, methylprednisolone, testosterone and about a hundred others. These go into creams, tablets and injections sold by other drug companies. It is one of the biggest suppliers in the world in its niche, sells in 40+ countries, and two of its top five customers are the original inventors of the drugs, which is a real mark of quality.
The company has spent twenty years earning approvals that are hard to get: its two plants have held US FDA and European certifications continuously since 2009 and 2012. Changing an ingredient supplier forces a drug maker to refile paperwork with regulators, so customers rarely leave: 69% of revenue comes from customers of more than seven years.
The new bet is moving up the chain. Instead of selling the ingredient by the kilogram, the company wants to sell the finished injection in a special two-chamber vial, starting with the two drugs where it already supplies most of the world's ingredient volume. It has built the plant; it has not yet won the approvals, signed a sales partner, or sold a single vial.
Easy or difficult business? The old business is genuinely difficult: making steroid ingredients to US and European standards takes years of regulatory work and few companies do it. The new business is a different kind of difficult that the company has not done before. Sterile injectable manufacturing, the vial device, and the drug-plus-device approvals are the real barrier, and those skills belong to the formulation world rather than the ingredient world.
Key numbers
| ₹ cr | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Revenue | 716.2 | 751.6 | 869.1 |
| Revenue growth % | n/a | 4.9 | 15.7 |
| Gross margin % | 55.2 | 60.4 | 63.7 |
| EBITDA | 177.0 | 206.1 | 232.0 |
| EBITDA margin % | 24.5 | 27.3 | 26.6 |
| PAT | 100.1 | 96.8 | 109.9 |
| PAT growth % | n/a | -3.2 | 13.6 |
Profit has grown at less than half the pace of revenue. The gross margin gain is real (making its own starting materials cut raw-material cost from 48% to 37% of product sales), but the running cost of the two new plants ate about half of it, and last year's reported profit growth came from a one-time ₹16 crore deferred-tax credit. Without it, profit fell for the second year running. About 3.8% of FY2026 revenue was also the release of a milestone payment banked back in FY2024, not a product sale.
The company reports one business segment, so the split below uses its own reconciliation of the core against the two new plants:
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Core ingredient business, revenue (₹ cr) | 716.2 | 744.8 | 835.0 |
| Core revenue growth % | n/a | 4.0 | 12.1 |
| Core operating profit (₹ cr) | 147.7 | 178.4 | 194.5 |
| New plants, operating result (₹ cr) | -9.5 | -15.4 | -15.8 |
Scorecard
| Block | Rating | Why |
|---|---|---|
| Right to win | MARGINAL | The moat in ingredients is real: an oligopoly market, twenty years of clean US and European inspections, customers who cannot switch without refiling, and making its own starting materials. But it protects a small pool the company has nearly filled, its share is falling in the three biggest products by value, and the forward move into injections rests on skills (sterile manufacturing, device approvals, selling finished drugs) the company has never demonstrated, with no signed partner and an 18-person sales team. |
| Industry and TAM | MARGINAL | The addressable pool is genuinely small and slow, about US$720 million growing 1 to 3% a year, and our outside checking confirmed that reflects a real capability boundary rather than a narrow definition. The big adjacent markets are real but the company has no revenue in them yet. |
| Financial momentum | MARGINAL | Good core, heavy drag: 63% of capital sits in plants earning nothing, group return on capital has fallen three years to 11.6%, and next year's arithmetic points down unless the new plants produce revenue. |
| Risks, governance, RPTs | MARGINAL | Clean where it matters most (almost no money leaves toward the promoters except salary; no group companies; a top-tier auditor), but ₹51 crore of tax reassessment notices sit at zero provision, the books' administrator-level change log was off for nearly three years, and a rival's court case asking that the offer be blocked was unresolved at filing. |
| Promoter and cap table | PASS | Twenty years of building plants on time without a loan default, ₹740 crore of capex absorbed while gearing fell, and a simple share count. The promoter's overseas side ventures have all failed, which is the caution against the new bets. |
| Offer structure | MARGINAL | The sellers are the right kind (two PE funds exiting after eight years at contractual hurdles) and the objects are clean, but 91% of the deal is exit, the fresh money funds nothing the strategy needs, and a promoter margin loan re-pledges 13.2% of the company two days after listing. |
Watch out for
- A US FDA inspection closed four days before the filing with four observations, response not yet filed (T1). The plant involved makes the hormone ingredients that cannot legally be made anywhere else in the company.
- The injectables plant stands on land a state master plan has zoned residential. The company holds a High Court stay and is the petitioner, but roughly a third of net worth sits on land whose permitted use has been unresolved since 2023 (T1).
- A rival has opened three legal fronts timed to the IPO, including a High Court writ naming SEBI that seeks a forensic audit of the company's data and asked that the offer not proceed (T1). It is an adversary's claim, unproven, and the offer is going ahead, but it was unresolved at the filing date.
- ₹51 crore of tax reassessment notices repeat the same alleged defect across four assessment years and are carried at zero provision (T1).
The offer
- Raising ₹1,757 crore in total: ₹150 crore of new money for the company and ₹1,607 crore of shares sold by existing holders, mostly the two private equity funds (T1).
- For repaying ₹113 crore of working-capital bank debt, plus general purposes. No factory or expansion is funded; the plants are already built.
- Implied valuation is in the table at the top.
- Promoters sell ₹144 crore through their family entity and keep about 33% of the company afterwards. Three of the four promoters sell nothing, and the family put more cash in during the past year than it takes out here, though it borrowed to do so.
Assessment from the RHP, with no outside verification beyond the price band and offer dates, which come from the NSE and BSE public records, and the outside checking noted on this page. Numbers carry source tiers: (T1) the filing's audited sections, (T3) mainstream news and secondary sources, UNVERIFIED where nothing supports them. Not a recommendation. The valuation section states what the announced band implies and is not a view on whether that price is right.